Details for Patent: 1,001,053
✉ Email this page to a colleague
Which drugs does patent 1,001,053 protect, and when does it expire?
Patent 1,001,053 protects NUBEQA, BELRAPZO, BENDEKA, and CLEVIPREX, and is included in four NDAs.
This patent has seventy patent family members in twenty-three countries.
Summary for Patent: 1,001,053
Title: | Carboxamide derivative and its diastereomers in stable crystalline form |
Abstract: | The present disclosure relates to solid crystalline forms of N--((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)-propan-2-yl)-5-(1-- hydroxyethyl)-1H-pyrazole-3-carboxamide (I) and the diastereomers thereof, and to methods for preparing such crystalline forms. Compound (I) and the diastereomers thereof are potent androgen receptor (AR) modulators useful as a medicament. ##STR00001## |
Inventor(s): | Tormakangas; Olli (Turku, FI), Heikkinen; Terhi (Lieto, FI) |
Assignee: | Orlon Corporation (Espoo, FI) |
Application Number: | 15/547,193 |
Patent Claim Types: see list of patent claims | Compound; Process; |
Drugs Protected by US Patent 1,001,053
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bayer Healthcare | NUBEQA | darolutamide | TABLET;ORAL | 212099-001 | Jul 30, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
Eagle Pharms | BELRAPZO | bendamustine hydrochloride | SOLUTION;INTRAVENOUS | 205580-001 | May 15, 2018 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Eagle Pharms | BENDEKA | bendamustine hydrochloride | SOLUTION;IV (INFUSION) | 208194-001 | Dec 7, 2015 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
Chiesi | CLEVIPREX | clevidipine | EMULSION;INTRAVENOUS | 022156-001 | Aug 1, 2008 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
Chiesi | CLEVIPREX | clevidipine | EMULSION;INTRAVENOUS | 022156-002 | Aug 1, 2008 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
Chiesi | CLEVIPREX | clevidipine | EMULSION;INTRAVENOUS | 022156-003 | Nov 8, 2013 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 1,001,053
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
Finland | 20150033 | Jan 30, 2015 |
PCT Information | |||
PCT Filed | January 28, 2016 | PCT Application Number: | PCT/FI2016/050054 |
PCT Publication Date: | August 04, 2016 | PCT Publication Number: | WO2016/120530 |
International Family Members for US Patent 1,001,053
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Denmark | 3250554 | ⤷ Try a Trial | |||
European Patent Office | 3250554 | ⤷ Try a Trial | |||
Spain | 2917549 | ⤷ Try a Trial | |||
Croatia | P20220998 | ⤷ Try a Trial | |||
Hungary | E058986 | ⤷ Try a Trial | |||
Japan | 2018503662 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |